Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

N/A
2(100.0%)
2Total
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT01617161Not ApplicableActive Not Recruiting

Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer

Role: collaborator

NCT02070328Recruiting

Registry Study for Proton Therapy Clinical Outcomes and Long-Term Follow-up

Role: collaborator

NCT02040610Not ApplicableUnknown

Hypofractionated Image Guided Proton Therapy for Low andIntermediate Risk Prostate Cancer

Role: lead

All 3 trials loaded